Erytech sells U.S. manufacturing facility and enters long-term supply agreement with Catalent

Erytech is evaluating valuable strategic options to leverage its Erycaps platform and its development and manufacturing capabilities with complementary assets and/or a broader corporate transaction

Erytech Pharma announced the sale of its U.S. manufacturing facility to Catalent, a leading contract development and manufacturing organization (CDMO) in advanced therapies.

Under the terms of an asset purchase agreement between Erytech and Catalent, it agreed to acquire Erytech’s state-of-the-art commercial-scale cell therapy manufacturing facility in Princeton, New Jersey, for a total consideration of US $ 44.5 million. Erytech’s current staff at the site of approximately 40 people will be offered Catalent’s employment.

The parties will also enter into a long-term supply agreement, under which Catalent will manufacture Erytech’s lead product candidate Eryaspase (Graspa) for clinical and commercial supply in the United States. Erytech has a Phase 1 trial in first-line pancreatic cancer ongoing in the United States and is in a continued dialogue with the U.S. FDA regarding a potential BLA submission for Graspa in hypersensitive ALL, now targeted in the third quarter of 2022, subject to FDA agreement on remaining outstanding information requests.

Catalent will also offer their expertise in late-stage and commercial manufacturing of advanced therapy medicinal products with respect to product characterization, commercial production, regulatory inspections, and approvals.

Erytech’s Princeton facility is a 30,900 sqft cutting edge manufacturing facility, designed with the flexibility to expand to support various cell therapy production requirements and capacities. Catalent intends to expand the Princeton site and leverage Erytech’s experienced staff to manufacture a broader portfolio of cell therapies. Erytech will retain its manufacturing site in Lyon, France and its expertise and capabilities in manufacturing process science to continue innovating in cell therapy manufacturing.

“In Catalent we have found a great partner for the manufacturing of our innovative red blood cell derived products, and we believe that this strategic partnership will meet our long-term manufacturing needs in the United States,” commented Gil Beyen, Chief Executive Officer of Erytech,”

“This acquisition is strategically important to Catalent’s commitment to support the development, clinical, and commercial supply of cell therapies to meet rapidly growing demand,” said Manja Boerman, Ph.D., President, Catalent Cell & Gene Therapy.